Artios Pharma has announced the appointment of Dr Simon Boulton as Vice President (VP) Science Strategy.
Dr Boulton will assist the business development team in the identification and evaluation of new pipeline opportunities from the global academic and industrial DDR network. He will also provide scientific leadership and support to the ongoing development of the two lead DDR programmes that Artios has in-licensed from Cancer Research Technology (CRT), the development and commercialisation arm of CRUK.
Known as a world-leading researcher in the field of DNA repair and the treatment of cancer resulting from DNA damage, he will join the newly formed leadership team at the company. He will perform the role alongside his current and principal position as Senior Group Leader at the Francis Crick Institute, London.
Artios Pharma is a newly-formed company that focusses on developing novel cancer treatments targeting the DNA Damage Response (DDR).
Dr Niall Martin, Chief Executive Officer of Artios Pharma, said: “Simon brings with him considerable DDR experience and a wealth of contacts and knowledge in the field, all of which will be invaluable as we continue to build a pipeline of first-in-class DDR programmes and establish Artios as a leading player in the DDR field.”